Oncologist Dr. Mikhail Blagosklonny Takes On Both Cancer And Aging

Many doctors and researchers dedicate their lives to just one field of research. One renowned Oncologist, however, is making his name known for research in both cancer and anti-aging research. For Dr. Mikhail Blagosklonny, working on treatments for both cancer and the effects of aging is a passion that has spanned for decades.

Dr. Blagosklonny’s research into both cancer and anti-aging can be traced back to his work with the cancer treatment drug Rapamycin. Also known as Sirolimus, this drug is used to help prevent organ transplant rejection. Further research by Dr. Blagosklonny has shown that Rapamycin has incredible immunosuppressive and antiproliferative properties that can be used in anti-aging treatment. Read Mikhail’s plans for Oncology on Healingmagic.net.

Dr. Blagosklonny’s research has shown that Rapamycin can be a useful treatment in the field of anti-aging and has advocated for the wider use of the drug. The Oncologist tested the drug on aging mice and found that the mice were able to deal with diseases such as tuberculosis.

Human tests on Rapamycin revealed immunological rejuvenation on a set of elderly patients. The drug was given to the patients before they received an influenza vaccination. While there is not yet conclusive proof that Rapamycin can increase human longevity, Dr. Blagosklonny advocates continuing research of the drug on a wide group of human test subjects.

Mikhail Blagosklonny’s research centers around his belief that cancer and anti-aging are both intertwined. And by using cancer drugs to treat aging, the population can see an overall increase in lifespan while seeing a decrease in cancer rates.

Learn more: https://classroomvoices.org/understanding-oncology-through-mikhail-blagosklonny/

This is what makes Rapamycin a big focus of Mikhail Blagosklonny’s research. The drug is one of the only known that can both fight cancer and aging. Some of the other impacts of Rapamycin on the human body include immunosuppressant properties, treatment for patients with the hemolytic-uremic syndrome, treatment of Lymphangioleiomyomatosis, coronary stent coating, treatment of tuberous sclerosis complex, treatment of Alzheimer’s disease and treatment of muscular dystrophy.

Dr. Mikhail Blagosklonny received his medical doctorate degree in internal medicine from the First Pavlov State Medical University of St. Petersburg. He also received a doctorate in experimental medicine and cardiology from the same university. Later he became an associate professor of medicine at New York Medical College in Valhalla, NY. Dr. Blagosklonny left that position a few years later to become a senior scientist at Ordway Research Institute. In 2009, Dr. Blagosklonny became a professor of oncology at Roswell Park Cancer Institute. He held that position until 2016.

Today, Dr. Blagosklonny is the foremost advocate for using cancer drugs for anti-aging treatment. The Oncologist’s tireless work has impacted thousands of people with the hope that millions can find an affordable and effective treatment for both cancer and diseases related to aging. Know more about Mikhail at Philly Purge.

Doubled Schedule and Efforts of Oncotarget

Oncotarget is one of the largest online medical journals written in English. It has a focus primarily on oncology, but in recent years Oncotarget has started publishing about several other disciplines in the biomedical field. Some of those include Pathology, Immunology, Chromosomes, and more.

Over the year, Oncotarget has been edited and reviewed by peers. Having other scientists and medical experts review the journal, and its publications make it more accurate and trustworthy. The numbers and other data in the journal are also coordinated with archives and indexes to assure accuracy. It is a priority for Oncotarget to provide reliable information for its readers- both practitioner and interested people of the general public. Visit Soundcloud to listen an audio podcast of Oncotarget.

Over the years, Oncotarget has been publishing one every week. A couple of months ago, the online biomedical journal announced that they would be doubling their output n order to provide more information for their audience. The journal will also be available in a variety of archives, including some of the most prestigious ones.

Oncotarget is peer-reviewed by dozens of scientists and biomedical experts in several disciplines. The online journal is continually trying to expand upon its content which will help them achieved their doubled schedule. The two Editors in Chief of Oncotarget are oncologists who also specialize in cardiology and aging.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

Dr. Andrei Gudkov is serving at the Roswell Park Cancer Institut. He conducts research in cardiology and oncology and teaches as a professor at a local university

Dr. Mikhail Blakosklonny used to work at the Roswell Park Cancer Institute as well. He was a senior scientist from 2009 till 2016. While he was working at the Institute, Dr. Mikhail Blagosklonny was also an editor for two other online medical journals called Cell Cycle and Aging. He is focused on his work as an editor.

Before assuming a position at the Rowell Park Cancer Institute, Dr. Mikhail Bagosklonny worked as a professor of medicine at a local college and then another research institute in New York. He has also made many contributions to a variety of journals and other medical publication detailing his progress in his research. Visit Oncotarget’s profile page at facebook.com